Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Selumetinib vs Carboplatin/Vincristine in Low-Grade Glioma
NCT04166409Phase 3Recruiting
- Sponsor
- National Cancer Institute
- Start
- Jan 2020
- Primary completion
- Dec 2030
- Countries
- 3
01
Overview
A Phase 3 trial of selumetinib in glioma, astrocytoma, sponsored by National Cancer Institute. Started Jan 2020; status: recruiting.
02
Drugs
selumetinib
03
Conditions
gliomaastrocytoma
Beyond the preview
Go deeper on NCT04166409.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04166409.